1. Home
  2. MRK vs SCLXW Comparison

MRK vs SCLXW Comparison

Compare MRK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merck & Company Inc. (new)

MRK

Merck & Company Inc. (new)

HOLD

Current Price

$108.43

Market Cap

260.2B

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.17

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRK
SCLXW
Founded
2000
N/A
Country
United States
United States
Employees
N/A
30
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
260.2B
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MRK
SCLXW
Price
$108.43
$0.17
Analyst Decision
Buy
Analyst Count
15
0
Target Price
$111.93
N/A
AVG Volume (30 Days)
13.9M
4.0K
Earning Date
02-03-2026
03-07-2025
Dividend Yield
3.12%
N/A
EPS Growth
58.08
N/A
EPS
7.56
N/A
Revenue
$64,235,000,000.00
$55,152,000.00
Revenue This Year
$1.98
N/A
Revenue Next Year
$4.94
N/A
P/E Ratio
$14.41
N/A
Revenue Growth
1.68
22.02
52 Week Low
$73.31
$0.18
52 Week High
$110.17
$0.18

Technical Indicators

Market Signals
Indicator
MRK
SCLXW
Relative Strength Index (RSI) 71.12 55.79
Support Level $104.43 $0.07
Resistance Level $107.59 $0.19
Average True Range (ATR) 2.09 0.03
MACD 0.20 0.01
Stochastic Oscillator 79.29 92.00

Price Performance

Historical Comparison
MRK
SCLXW

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: